Aug 8, 2026 12:00PM
Aug 7, 2026 08:00AM
Aug 3, 2026 07:31AM
Aug 3, 2026 07:30AM
Jul 28, 2026 07:45AM
Jul 28, 2026 07:45AM
Jul 23, 2026 08:01AM Lantern Pharma receives USPTO patent allowance for LP-184 biomarker
Jul 23, 2026 08:01AM
Jul 8, 2026 07:30AM
Jul 8, 2026 07:30AM
Jun 2, 2026 08:15AM
Jun 2, 2026 08:13AM
May 19, 2026 07:30AM
May 19, 2026 07:30AM Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
May 15, 2026 04:01PM
May 14, 2026 04:05PM
May 14, 2026 04:05PM
May 14, 2026 04:05PM
May 13, 2026 08:00AM
May 13, 2026 08:00AM
May 11, 2026 04:30PM Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
May 7, 2026 09:01AM
May 7, 2026 09:01AM
Apr 29, 2026 08:50AM
Apr 24, 2026 07:50AM
Apr 20, 2026 08:05AM
Apr 20, 2026 08:05AM
Apr 14, 2026 08:36AM Lantern Pharma launches withZeta.ai commercial platform for cancer research
Apr 14, 2026 08:31AM
Apr 2, 2026 08:10AM
Mar 30, 2026 04:05PM
Mar 27, 2026 07:29AM
Mar 27, 2026 07:29AM
Mar 23, 2026 04:30PM
Feb 10, 2026 08:45AM Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
Jan 20, 2026 08:04AM
Jan 20, 2026 08:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 3, 2025 08:35AM
Dec 3, 2025 08:35AM
Nov 13, 2025 08:30AM Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
Nov 6, 2025 08:00AM
Oct 30, 2025 08:00AM
Oct 28, 2025 08:50AM
Oct 28, 2025 08:49AM
Oct 24, 2025 08:00AM
Sep 16, 2025 08:29AM
Sep 16, 2025 08:29AM Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
Sep 3, 2025 09:44AM

328,448 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All